CObalt chromium STent with Antiproliferative for Restenosis Trial in India (COSTAR I)

Indian Heart Journal

Volumn 59, Issue 2, 2007, Pages 165-172

  Kaul, Upendra ^a   Gupta, Ripen K ^a   Mathur, Atul ^b   Dani, Sameer ^c   Sapra, Rakesh ^a   Nayak, P Ranganath ^d   Lansky, Alexandra ^e   Cristea, Ecaterina ^e   Carlier, Stephane ^e   Gambone, Louise ^f   Litvack, Frank ^f  

^a FORTIS HOSPITAL   (India)

^b ESCORTS HEART INSTITUTE AND RESEARCH CENTRE   (India)

^c SAL Hospital and Medical Institute   (India)

^d Wockhardt Hospitals India   (India)

^e CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^f Conor Medsystems ^*  (United States)

Author keywords

Coronary artery disease; Paclitaxel; Restenosis; Stent

Indexed keywords

CHROMIUM; COBALT; PACLITAXEL; POLYMER;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BIOSORPTION; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY BLOOD VESSEL; CORONARY STENT; DEMOGRAPHY; DOSE RESPONSE; DRUG ELUTING STENT; DRUG FORMULATION; DRUG SAFETY; FEMALE; HUMAN; INDIA; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; RESTENOSIS; SURVIVAL; TREATMENT OUTCOME;

ABSORBABLE IMPLANTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHROMIUM; COBALT; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; FEASIBILITY STUDIES; FEMALE; HEALTH STATUS INDICATORS; HUMANS; INDIA; MALE; MIDDLE AGED; PACLITAXEL; POLYMERS; PROSPECTIVE STUDIES; REGISTRIES; RISK FACTORS; TRACE ELEMENTS; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 37849009408     PISSN: 00194832     EISSN: 00194832     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Grube E, Silber S, Hauptmann KE, et al. Six and twelve-months results from a randomized, double blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003;107:38-42.
2. Columbo A, Drzewiecki J, Banning A, et al. Randomized study to assess the effectiveness of slow-and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003;108:788-94.
3. Stone GW, Ellis SG, Cox DA, et al. A polymer-based paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-31.
4. Stone GW, Ellis SG; Cannon L, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized control trial. JAMA 2005;294:1215-23.
5. Dawkins KD, Grube E, Guagliumi G, et al. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial. Circulation 2005;112:3306-13.
6. Morice M-C, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-80.
7. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stent vs. standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23.
8. Schofer J, Schlüter M, Gershlick AH, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003;362:1093-99.
9. Grube E, Lansky A, Hauptmann KE, et al. High-dose 7-Hexanoyltaxol-eluting stent with polymer sleeves for coronary revascularization: One year results from the SCORE Trial. J Am Coll Cardiol 2004;44:1368-72.
10. Ong ATL, McFadden EP, Regar E, et al. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 2005;45:2088-92.
11. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors and outcomes of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-30.
12. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stent in humans. J Am Coll Cardiol 2006;48:193-02.
13. Colombo A, Corbett SJ. Drug-eluting stent thrombosis. J Am Coll Cardiol 2006;48:203-05.
14. Virmani R, Liistro F, Stankovic G, et al. Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation 2002;106:2649-51.
15. Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 2004;109:701-05.
16. Axel DI, Kunert W, Göggelman C, et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Ciculation 1997;96:636-45.
17. Rowinsky EK, Donehower RC. Drug Therapy: Paclitaxel (Taxol). N Engl J Med 1995;332:1004-14.
18. Kereiakes DJ. Coronary small-vessel stenting in the era of drug elution. Rev Cardiovasc Med 2004;5;S34-45.
19. Kastrati A, Dibra A, Mehilli M, et al. Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents. Circulation 2006;113:2293-300.
20. Mehran R, Dangas G, Kobayashi Y, et al. Short- and long-term results after multivessel stenting in diabetic patients. J Am Coll Cardiol 2004;43:1348-54.
21. Bavry AA, Kumbhani DJ, Helton TJ, et al. What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention? A meta-analysis. J Am Coll Cardiol 2005;45:941-46.
22. Aoki J, Ong ATL, Abizaid A, et al. One-year clinical outcomes of various dose and pharmacokinetic release formulations of paclitaxel eluted from an erodable polymer-Insight in the Paclitaxel In-Stent Controlled Elution Study (PISCES). EuroInterv 2005;1:165-72.